Hot Investor Mandate 1: Family Office Seeks Novel Therapeutic Platforms From Preclinical-Phase II

19 May

A family office investment vehicle based in New York City is looking to provide equity capital to high growth companies in the life science space usually in Series A or B rounds. The firms typically deal size is highly variable generally going as high as $5million for an initial investment. and depends on each individuals companies position and funding needs. The firm is currently interested in companies located throughout the US and Canada and is looking to make approximately 2-3 investments over the next year months.

The firm is currently looking for companies developing therapeutics. The firm is opportunistic in terms of sub sector and indication, but has a preference for companies with platform technologies. The firm is not interested in biosimilar or reformulation type opportunities. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials.

The firm looks to invest in companies with experienced management teams and is very open to investing in syndicates. The firm is interested in investing into pre-revenue firms, although the firm will not consider making seed stage investments. The firm is capable to act as either a lead or a co-investor and generally seeks board or board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: